# First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

> **NCT03507452** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma
- Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
- Advanced Recurrent Serous Ovarian Cancer
- Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

## Interventions

- **DRUG:** BAY2287411
- **DRUG:** BAY2287411

## Key facts

- **NCT ID:** NCT03507452
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2021-09-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507452, "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03507452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*